Efficacy and safety of tyrosine kinase inhibitors’
discontinuation after twostep dose reduction in patients with
chronic myeloid leukemia – a prospective multi-centre phase II
clinical trial (HALF).

a 2021

Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).

ŽÁČKOVÁ, Daniela, Edgar FABER, L. STEJSKAL, M. KARAS, P. BĚLOHLÁVKOVÁ et. al.

Basic information

Original name

Authors

ŽÁČKOVÁ, Daniela (203 Czech Republic, guarantor, belonging to the institution), Edgar FABER (703 Slovakia, belonging to the institution), L. STEJSKAL, M. KARAS, P. BĚLOHLÁVKOVÁ, H. KLAMOVÁ, O. ČERNÁ, Eduard CMUNT (203 Czech Republic), Petra ČIČÁTKOVÁ (203 Czech Republic, belonging to the institution), Lukáš SEMERÁD (203 Czech Republic, belonging to the institution), Tomáš HORŇÁK (703 Slovakia, belonging to the institution), Anežka KVETKOVÁ (703 Slovakia), Jiřina PROCHÁZKOVÁ (203 Czech Republic), Jitka RYCHLÍČKOVÁ (203 Czech Republic, belonging to the institution), Radka ŠTĚPÁNOVÁ (203 Czech Republic, belonging to the institution), Adam SVOBODNÍK (203 Czech Republic, belonging to the institution), Kateřina MACHOVÁ POLÁKOVÁ (203 Czech Republic), Ivana JEŽÍŠKOVÁ (203 Czech Republic, belonging to the institution), Tomáš JURČEK (203 Czech Republic), Marek BORSKÝ (203 Czech Republic, belonging to the institution), Ondřej WIEWIORKA (203 Czech Republic, belonging to the institution) and Jiří MAYER (203 Czech Republic, belonging to the institution)

Edition

23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021, 2021

Other information

Language

English

Type of outcome

Konferenční abstrakt

Field of Study

30205 Hematology

Country of publisher

France

Confidentiality degree

není předmětem státního či obchodního tajemství

RIV identification code

RIV/00216224:14110/21:00124702

Organization unit

Faculty of Medicine

Keywords in English

tyrosine kinase inhibitors; chronic myeloid leukemia

Abstract

V originále

Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF) - conference abstract from 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021.

Links

LM2018128, research and development project

Name: Český národní uzel Evropské sítě infrastruktur klinického výzkumu (Acronym: CZECRIN)

Investor: Ministry of Education, Youth and Sports of the CR

Citovat

ŽÁČKOVÁ, Daniela, Edgar FABER, L. STEJSKAL, M. KARAS, P. BĚLOHLÁVKOVÁ, H. KLAMOVÁ, O. ČERNÁ, Eduard CMUNT, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Tomáš HORŇÁK, Anežka KVETKOVÁ, Jiřina PROCHÁZKOVÁ, Jitka RYCHLÍČKOVÁ, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK, Kateřina MACHOVÁ POLÁKOVÁ, Ivana JEŽÍŠKOVÁ, Tomáš JURČEK, Marek BORSKÝ, Ondřej WIEWIORKA and Jiří MAYER. Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF). In 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021. 2021.

@proceedings{1830779,
   author = {Žáčková, Daniela and Faber, Edgar and Stejskal, L. and Karas, M. and Bělohlávková, P. and Klamová, H. and Černá, O. and Cmunt, Eduard and Čičátková, Petra and Semerád, Lukáš and Horňák, Tomáš and Kvetková, Anežka and Procházková, Jiřina and Rychlíčková, Jitka and Štěpánová, Radka and Svobodník, Adam and Machová Poláková, Kateřina and Ježíšková, Ivana and Jurček, Tomáš and Borský, Marek and Wiewiorka, Ondřej and Mayer, Jiří},
   booktitle = {23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021},
   keywords = {tyrosine kinase inhibitors; chronic myeloid leukemia},
   language = {eng},
   title = {Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).},
   year = {2021}
}

TY  - CONF
ID  - 1830779
AU  - Žáčková, Daniela - Faber, Edgar - Stejskal, L. - Karas, M. - Bělohlávková, P. - Klamová, H. - Černá, O. - Cmunt, Eduard - Čičátková, Petra - Semerád, Lukáš - Horňák, Tomáš - Kvetková, Anežka - Procházková, Jiřina - Rychlíčková, Jitka - Štěpánová, Radka - Svobodník, Adam - Machová Poláková, Kateřina - Ježíšková, Ivana - Jurček, Tomáš - Borský, Marek - Wiewiorka, Ondřej - Mayer, Jiří
PY  - 2021
TI  - Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF).
KW  - tyrosine kinase inhibitors
KW  - chronic myeloid leukemia
N2  - Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF) - conference abstract from 23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021.
ER  -

ŽÁČKOVÁ, Daniela, Edgar FABER, L. STEJSKAL, M. KARAS, P. BĚLOHLÁVKOVÁ, H. KLAMOVÁ, O. ČERNÁ, Eduard CMUNT, Petra ČIČÁTKOVÁ, Lukáš SEMERÁD, Tomáš HORŇÁK, Anežka KVETKOVÁ, Jiřina PROCHÁZKOVÁ, Jitka RYCHLÍČKOVÁ, Radka ŠTĚPÁNOVÁ, Adam SVOBODNÍK, Kateřina MACHOVÁ POLÁKOVÁ, Ivana JEŽÍŠKOVÁ, Tomáš JURČEK, Marek BORSKÝ, Ondřej WIEWIORKA and Jiří MAYER. Efficacy and safety of tyrosine kinase inhibitors’ discontinuation after twostep dose reduction in patients with chronic myeloid leukemia – a prospective multi-centre phase II clinical trial (HALF). In \textit{23rd Annual John Goldman E-Conference on Chronic Myeloid Leukemia: Biology and Therapy, ESHCML2021}. 2021.

Detailed Information on Publication Record